2022
DOI: 10.3389/fonc.2022.1029976
|View full text |Cite
|
Sign up to set email alerts
|

The current role of secondary cytoreductive surgery for recurrent ovarian cancer

Abstract: Ovarian cancer represents worldwide the second most frequent and the most fatal gynecological malignancy, with approximately two thirds of the patients presenting with advanced disease. Cytoreductive surgery, primary or after neoadjuvant chemotherapy, in combination with platinum-based chemotherapy is the standard of care for these patients. Despite the improvement in quality of cytoreductive surgery as well as development of novel drugs and chemotherapy regimens, still most women with ovarian cancer will ulti… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1

Citation Types

0
3
0

Year Published

2023
2023
2024
2024

Publication Types

Select...
7

Relationship

0
7

Authors

Journals

citations
Cited by 7 publications
(3 citation statements)
references
References 87 publications
0
3
0
Order By: Relevance
“…However, obtaining such samples is challenging due to the rarity of secondary cytoreductive surgery in platinum-refractory patients. The scarcity of these samples could pose a significant limitation to conducting such studies [49,50].…”
Section: Discussionmentioning
confidence: 99%
“…However, obtaining such samples is challenging due to the rarity of secondary cytoreductive surgery in platinum-refractory patients. The scarcity of these samples could pose a significant limitation to conducting such studies [49,50].…”
Section: Discussionmentioning
confidence: 99%
“…Cytoreductive surgery is often included in frontline treatment of ovarian cancer and has been associated with significant survival benefit, particularly in patients with primary platinum resistance who may derive less benefit from platinum-based chemotherapy . Secondary cytoreductive surgery (SCS) in the recurrent setting has only been prospectively evaluated in platinum-sensitive ovarian cancer, where clear criteria have been developed .…”
Section: Evolution Of Proc Treatment and Recent Developmentsmentioning
confidence: 99%
“…Patients with single or oligometastatic recurrences can be offered minimally invasive secondary cytoreductive surgery, mainly if localized in the lymph nodes, and/or receive neoadjuvant chemotherapy at primary diagnosis [8][9][10][11][12][13]. Hyperthermic intraperitoneal chemotherapy (HIPEC) after cytoreductive surgery has been extensively studied in patients with peritoneal carcinomatosis, and it holds promise as a therapeutic strategy in both primary and recurrent scenarios.…”
Section: Introductionmentioning
confidence: 99%